TY - JOUR
TI - The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema
AU - Chatziralli, I.
AU - Papadakou, P.
AU - Dimitriou, E.
AU - Kazantzis, D.
AU - Kapsis, P.
AU - Theodossiadis, G.
AU - Papathanassiou, M.
AU - Theodossiadis, P.
JO - Cutaneous and Ocular Toxicology (formerly Journal of Toxicology - Cutaneous and Ocular Toxicology)
PY - 2021
VL - 40
TODO - 2
SP - 66-69
PB - Taylor and Francis Ltd.
SN - 1556-9527, 1556-9535
TODO - 10.1080/15569527.2021.1887886
TODO - aflibercept;  hemoglobin A1c;  ranibizumab;  aflibercept;  angiogenesis inhibitor;  fusion protein;  ranibizumab;  vasculotropin;  vasculotropin receptor, adult;  Article;  best corrected visual acuity;  cell density;  cell size;  central corneal thickness;  central retinal thickness;  clinical article;  comorbidity;  controlled study;  cornea endothelium;  diabetic macular edema;  engineering;  female;  fluorescence angiography;  follow up;  human;  intraocular pressure;  loading drug dose;  male;  middle aged;  optical coherence tomography;  prospective study;  slit lamp microscopy;  spectral domain optical coherence tomography;  specular microscopy;  aged;  clinical trial;  cornea endothelium;  diabetic complication;  drug effect;  intravitreal drug administration;  macular edema;  visual acuity, Aged;  Angiogenesis Inhibitors;  Diabetes Complications;  Endothelium, Corneal;  Female;  Humans;  Intravitreal Injections;  Macular Edema;  Male;  Middle Aged;  Ranibizumab;  Receptors, Vascular Endothelial Growth Factor;  Recombinant Fusion Proteins;  Tomography, Optical Coherence;  Vascular Endothelial Growth Factors;  Visual Acuity
TODO - Purpose: To evaluate the characteristics of corneal parameters in patients with diabetic macular oedema (DME) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Methods: Participants in this study were 36 patients with DME, treated with either intravitreal ranibizumab (n = 16) or aflibercept (n = 20). All participants underwent best-corrected visual acuity (BCVA) measurement, optical coherence tomography and non-contact specular microscopy to evaluate corneal endothelium parameters (endothelial cell density-ECD, hexagonality, coefficient of variation of the cell size and central corneal thickness-CCT), at baseline and at months 6 and 12 after the first intravitreal injection. Comparisons between baseline and months 6 and 12 were performed. Results: There was no statistically significant difference regarding ECD, hexagonality, coefficient of variation of the cell size and CCT at month 6 and 12 post initial injection compared to baseline in patients with DME. BCVA improved significantly at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Central retinal thickness was significantly reduced at month 6 and 12 compared to baseline (p < 0.001 for both comparisons). Conclusion: Intravitreal anti-VEGF injections in patients with DME were found not to affect corneal parameters, namely ECD, hexagonality, coefficient of variation of the cell size and CCT at the long-term follow-up of 12 months. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
ER -